- Home
- DBVT vs IVA Comparison
DBVT vs IVA Comparison
Compare DBVT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBVT | IVA |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | France | France |
| Employees | 90 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.9M | 737.1M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBVT | IVA |
|---|---|---|
| Price | $9.50 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $37.66 | $15.20 |
| AVG Volume (30 Days) | 380.8K | ★ 2.8M |
| Earning Date | 10-28-2026 | 09-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,636,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,633.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.77 | N/A |
| 52 Week Low | $8.63 | $2.82 |
| 52 Week High | $26.19 | $7.29 |
Technical Indicators
Market Signals| Indicator | DBVT | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 53.95 |
| Support Level | $8.63 | $3.35 |
| Resistance Level | $14.90 | $3.76 |
| Average True Range (ATR) | 0.54 | 0.23 |
| MACD | 0.19 | 0.09 |
| Stochastic Oscillator | 35.87 | 79.90 |
Price Performance
Historical ComparisonAbout DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.